B. Riley Equities Analysts Cut Earnings Estimates for RadNet

RadNet, Inc. (NASDAQ:RDNT) – Analysts at B. Riley cut their FY2025 EPS estimates for RadNet in a research report issued on Sunday, November 30th. B. Riley analyst Y. Zhi now anticipates that the medical research company will post earnings of $0.38 per share for the year, down from their prior estimate of $0.39. B. Riley has a “Buy” rating and a $87.00 price objective on the stock. The consensus estimate for RadNet’s current full-year earnings is $0.56 per share. B. Riley also issued estimates for RadNet’s Q4 2025 earnings at $0.21 EPS.

A number of other brokerages have also issued reports on RDNT. Zacks Research lowered RadNet from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 12th. Barclays increased their target price on shares of RadNet from $79.00 to $86.00 and gave the stock an “overweight” rating in a report on Thursday, November 13th. Morgan Stanley upgraded shares of RadNet to an “overweight” rating in a research note on Monday, August 11th. Weiss Ratings restated a “sell (d-)” rating on shares of RadNet in a research note on Monday. Finally, Truist Financial raised their price objective on RadNet from $81.00 to $90.00 and gave the company a “buy” rating in a report on Wednesday, November 12th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $87.60.

RadNet Stock Performance

RDNT opened at $78.80 on Wednesday. The company has a market capitalization of $6.08 billion, a price-to-earnings ratio of -393.98 and a beta of 1.48. The business’s 50-day moving average price is $78.17 and its two-hundred day moving average price is $67.53. RadNet has a 1 year low of $45.00 and a 1 year high of $85.84. The company has a debt-to-equity ratio of 0.91, a current ratio of 2.00 and a quick ratio of 2.00.

RadNet (NASDAQ:RDNT) last issued its quarterly earnings data on Monday, November 10th. The medical research company reported $0.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by ($0.03). The company had revenue of $522.87 million for the quarter, compared to the consensus estimate of $494.19 million. RadNet had a positive return on equity of 2.41% and a negative net margin of 0.78%.The firm’s revenue was up 13.4% on a year-over-year basis. During the same period in the prior year, the company earned $0.18 EPS.

Hedge Funds Weigh In On RadNet

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Headlands Technologies LLC bought a new stake in shares of RadNet during the 1st quarter worth about $28,000. Allworth Financial LP boosted its holdings in shares of RadNet by 346.6% during the third quarter. Allworth Financial LP now owns 393 shares of the medical research company’s stock worth $30,000 after acquiring an additional 305 shares during the period. Danske Bank A S acquired a new position in shares of RadNet in the third quarter valued at approximately $30,000. Farther Finance Advisors LLC increased its stake in shares of RadNet by 1,086.5% during the third quarter. Farther Finance Advisors LLC now owns 439 shares of the medical research company’s stock worth $33,000 after purchasing an additional 402 shares during the period. Finally, Jones Financial Companies Lllp increased its stake in shares of RadNet by 62.2% during the third quarter. Jones Financial Companies Lllp now owns 446 shares of the medical research company’s stock worth $34,000 after purchasing an additional 171 shares during the period. 77.90% of the stock is owned by institutional investors.

Insider Activity

In other RadNet news, EVP Mark Stolper sold 35,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $73.89, for a total transaction of $2,586,150.00. Following the transaction, the executive vice president owned 68,012 shares of the company’s stock, valued at $5,025,406.68. The trade was a 33.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Cornelis Wesdorp sold 500 shares of the company’s stock in a transaction that occurred on Thursday, September 11th. The shares were sold at an average price of $72.13, for a total value of $36,065.00. Following the completion of the sale, the chief executive officer owned 53,495 shares in the company, valued at $3,858,594.35. This represents a 0.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 96,000 shares of company stock valued at $7,287,864 in the last 90 days. 5.60% of the stock is owned by company insiders.

RadNet Company Profile

RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services.